Precigen (NASDAQ:PGEN) Stock Price Down 15.9% – Here’s What Happened

Precigen, Inc. (NASDAQ:PGEN)’s stock price traded down 15.9% during trading on Thursday. The company traded as low as $4.10 and last traded at $4.2460. Approximately 3,990,953 shares traded hands during trading, a decline of 17% from the average daily volume of 4,823,642 shares. The stock had previously closed at $5.05.

Precigen News Summary

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised its earnings forecasts for Precigen across Q4 2026 and each quarter of 2027, while maintaining a Buy rating and an $18 price target. HC Wainwright estimates and rating
• Positive Sentiment: Citizens JMP raised its price target from $11 to $12 and reiterated a Market Outperform rating, adding to the bullish analyst outlook. Citizens JMP price target
• Positive Sentiment: Precigen’s Q3 revenue of $74.1 million topped the cited FactSet estimate of $71.5 million. The reported $0.08 per-share earnings beat some estimates but fell short of the higher Zacks consensus, making the earnings picture mixed. Q3 revenue results
• Negative Sentiment: A valuation analysis argues that PGEN may already be fully priced based on current earnings, which could limit further upside if future growth does not meet expectations. Precigen valuation analysis

Analyst Upgrades and Downgrades

PGEN has been the subject of a number of research analyst reports. Citigroup reaffirmed a “market outperform” rating on shares of Precigen in a research note on Thursday. Raymond James Financial set a $12.00 price target on shares of Precigen in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Thursday, October 15th. Zacks Research cut shares of Precigen from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 5th. Finally, HC Wainwright boosted their price objective on shares of Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Precigen Stock Up 5.9%

The firm has a 50 day simple moving average of $6.98 and a two-hundred day simple moving average of $5.28. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 3.89. The stock has a market cap of $1.59 billion, a price-to-earnings ratio of 44.70 and a beta of 1.01.

Precigen (NASDAQ:PGEN) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The firm had revenue of $74.15 million for the quarter, compared to analysts’ expectations of $71.55 million. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%. The company’s revenue was up 2437.6% compared to the same quarter last year. During the same quarter last year, the business earned ($1.06) earnings per share. As a group, sell-side analysts expect that Precigen, Inc. will post 0.23 EPS for the current year.

Insider Activity at Precigen

In related news, COO Rutul R. Shah sold 34,658 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $7.50, for a total transaction of $259,935.00. Following the completion of the transaction, the chief operating officer owned 465,012 shares in the company, valued at approximately $3,487,590. The trade was a 6.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey B. Kindler sold 185,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the completion of the sale, the director directly owned 17,100 shares of the company’s stock, valued at $127,224. The trade was a 91.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 235,000 shares of company stock worth $1,751,400 in the last three months. 41.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Precigen

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. State of Wyoming bought a new position in Precigen during the first quarter worth about $27,000. Royal Bank of Canada grew its stake in Precigen by 102.6% in the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 5,426 shares during the period. Chicago Partners Investment Group LLC bought a new stake in shares of Precigen in the first quarter worth about $43,000. Carolina Wealth Advisors LLC bought a new stake in shares of Precigen in the third quarter worth about $46,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Precigen in the first quarter worth about $49,000. 33.51% of the stock is owned by institutional investors.

Precigen Company Profile

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen’s pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.